The online portal available on the Indian Council of Medical Research (ICMR) site will be a repository for all information related to vaccine development in India. You can access the website from here.
“Everyone will be able to go online to that portal to find all the contemporary information related to research, development and clinical trials on such vaccines,” Vardhan said during the press conference on the ICMR 100-year timeline.
Previous reports suggest that in the first stage, the ICMR vaccine portal will reflect the information on the development of the Covid-19 vaccine in India. However, over time, the web portal will be strengthened with the data available for all vaccines used to prevent various diseases.
“The ICMR has always tried to meet the growing demands of scientific advances in biomedical research on the one hand, and the need to find practical solutions to the country’s health problems, on the other,” the portal reads.
Vardhan during the press conference praised ICMR’s efforts and contributions in the field of science. “It is an honor for me to publish the ICMR’s 100-year history schedule within its facilities today. The contribution of the scientists associated with it is commemorated and inspires future scientists,” added the minister.
India is currently in different phases of clinical trials of three Covid-19 vaccines.
The phase III or last stage of the clinical trial of the Covid-19 ‘Covishield’ vaccine, which is being developed by the University of Oxford and manufactured by the Serum Institute of India (SII), began on Monday at the state Sassoon General Hospital. in Pune, Maharashtra on Monday, a senior official said.
The Covishield vaccine will be administered as a dose to between 150 and 200 volunteers, the official said.
Indian indigenous vaccine developers, Bharat Biotech International Ltd., are in the second phase human trial stage and Zydus Cadila is in the process of receiving approvals for third phase clinical trials.
Currently, the government of Uttar Pradesh announced that the phase 3 trial of the coronavirus vaccine ‘COVAXIN’ will start in Lucknow and Gorakhpur from October.
Additionally, the Indian vaccine manufacturer recently announced a licensing agreement with the University of Washington School of Medicine in the US for a single-dose intranasal vaccine for COVID-19 based on a novel chimpanzee adenovirus. . The pact gives the Hyderabad-based vaccine developer the rights to distribute the vaccine in all markets except the US, Japan and Europe, it reported. mint.
Under the pact, phase I trials will be carried out at the university’s Vaccine Evaluation and Treatment Unit, while Bharat Biotech will undertake new stages of clinical trials in India and large-scale manufacturing of the vaccine at its facilities. in Genome Valley, Hyderabad.
IBS has also started manufacturing the Covid-19 candidate vaccine developed by Codagenix Inc, the American biotech said in a statement.
Nicknamed CDX-005, the coronavirus vaccine candidate has completed preclinical studies in animals. The drug maker aims to start the phase I clinical trial of its COVID-19 vaccine in the UK later this year.
Meanwhile, Serum CEO Adar Poonawalla called the distribution of a Covid-19 vaccine to 1.3 billion Indians “a worrying challenge,” he said the government may ₹80,000 crore over the next year for the distribution of the covid-19 vaccine to all people in India.
.
